Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah A Holstein

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Leukemia Research|September 11, 2010
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cellsSarah A Holstein, Raymond J Hohl
The Lancet. Haematology|July 5, 2016
Improved survival with salvage autologous stem-cell transplantation in myelomaSarah A Holstein, Philip L McCarthy
Drugs|April 19, 2021
Evolution of Treatment Paradigms in Newly Diagnosed Multiple MyelomaRadowan A Elnair, Sarah A Holstein
Journal of Lipid Research|April 3, 2003
Monoterpene regulation of Ras and Ras-related protein expressionSarah A Holstein, Raymond J Hohl
Cancer Reports (Hoboken, N.J.)|October 31, 2025
Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and DevelopmentStaci L Haney, Sarah A Holstein
Clinical Pharmacology and Therapeutics|October 18, 2019
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in ProgressSarah A Holstein, Matthew A Lunning
Drugs|February 17, 2017
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical ExperienceSarah A Holstein, Philip L McCarthy
Clinical Pharmacology and Therapeutics|June 3, 2020
Oncology Treatment in the Era of COVID-19: We Cannot Afford to Hit the Pause ButtonSarah A Holstein, Julie M Vose
The Lancet. Oncology|November 25, 2015
Continued role for ASCT in multiple myelomaPhilip L McCarthy, Sarah A Holstein
Current Opinion in Pharmacology|July 24, 2012
Is there a future for prenyltransferase inhibitors in cancer therapy?Sarah A Holstein, Raymond J Hohl
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Leukemia Research|September 11, 2010
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cellsSarah A Holstein, Raymond J Hohl
The Lancet. Haematology|July 5, 2016
Improved survival with salvage autologous stem-cell transplantation in myelomaSarah A Holstein, Philip L McCarthy
Drugs|April 19, 2021
Evolution of Treatment Paradigms in Newly Diagnosed Multiple MyelomaRadowan A Elnair, Sarah A Holstein
Journal of Lipid Research|April 3, 2003
Monoterpene regulation of Ras and Ras-related protein expressionSarah A Holstein, Raymond J Hohl
Cancer Reports (Hoboken, N.J.)|October 31, 2025
Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and DevelopmentStaci L Haney, Sarah A Holstein
Clinical Pharmacology and Therapeutics|October 18, 2019
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in ProgressSarah A Holstein, Matthew A Lunning
Drugs|February 17, 2017
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical ExperienceSarah A Holstein, Philip L McCarthy
Clinical Pharmacology and Therapeutics|June 3, 2020
Oncology Treatment in the Era of COVID-19: We Cannot Afford to Hit the Pause ButtonSarah A Holstein, Julie M Vose
The Lancet. Oncology|November 25, 2015
Continued role for ASCT in multiple myelomaPhilip L McCarthy, Sarah A Holstein
Current Opinion in Pharmacology|July 24, 2012
Is there a future for prenyltransferase inhibitors in cancer therapy?Sarah A Holstein, Raymond J Hohl
Pageof 14